Literature DB >> 10669043

Endogenous ATP released by electrical field stimulation causes contraction via P2x- and P2y-purinoceptors in the isolated tail artery of rats.

A Fukumitsu1, Y Takano, A Iki, K Honda, R Saito, T Katsuragi, H Kamiya.   

Abstract

Electrical field stimulation (EFS) caused contraction of isolated tail arteries of rats. The EFS-induced contraction showed frequency-dependence and was entirely abolished by the sodium channel blocker tetrodotoxin (1 x 10(-7) M). The EFS-induced (at 20 Hz) contraction was reduced by about 60% in the presence of phentolamine (1 x 10(-6) M). Therefore, later experiments were carried out in the presence of phentolamine. Pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) (1 x 10(-8)-1 x 10(-6) M) and basilen blue E-3G (3 x 10(-5)-5 x 10(-5) M), P2-receptor antagonists, significantly inhibited the contraction evoked by EFS. In addition, PPADS significantly inhibited the contractions induced by ATP (1 x 10(-4) M) and a selective P2x-receptor agonist, alpha,beta-methylene ATP (1 x 10(-6) M). In contrast, basilen blue E-3G did not inhibit alpha,beta-methylene ATP-induced contraction. The ecto-ATPase activator apyrase (5 and 10 U/ml) significantly reduced the EFS-induced contractions. These findings suggest that endogenous ATP released by EFS causes contractions of rat tail artery via both the P2x-receptors and P2y-receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10669043     DOI: 10.1254/jjp.81.375

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  2 in total

1.  Chronic decentralization potentiates neurovascular transmission in the isolated rat tail artery, mimicking the effects of spinal transection.

Authors:  Melanie Yeoh; Elspeth M McLachlan; James A Brock
Journal:  J Physiol       Date:  2004-10-14       Impact factor: 5.182

Review 2.  Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system.

Authors:  Vera Jankowski; Markus van der Giet; Harald Mischak; Michael Morgan; Walter Zidek; Joachim Jankowski
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.